Just having a quick search (maybe LED will have a more...

Just having a quick search (maybe LED will have a more detailed/correct explanation): The company is already relatively mature and already has a number of approvals under its belt (8 approved).



So an approval for Incyte is less of a big deal, particularly if the approved indication is for a relatively smaller market relative to their other current approvals.

Completely different to a company like Mesoblast that is still pre-commercialisation and doesn't have an approval with the FDA, which would be much more of a bigger deal relatively speaking: proof of concept, opens the door for future approvals (off label and label extensions), materially increases the companies revenue prospects... a first time approval is game changing: not so much for a mature company (unless it's completely game changing or significantly increases revenue prospects compared to their current revenue streams).